Nurix Therapeutics officer proposes $284K share sale
The notice also records four earlier sales under a Rule 10b5-1 plan between August 3 and October 2, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Nurix Therapeutics, Inc. officer Christine Ring reported a proposed sale of 10,602 common shares, with an aggregate market value of $284,133.60 and an approximate sale date of November 2, 2026.
The notice also lists four sales under a Rule 10b5-1 plan during the preceding three months: 5,787 shares on August 3, 2026; 10,802 shares on August 3, 2026; 5,787 shares on September 2, 2026; and 5,786 shares on October 2, 2026.
Key Figures
Key Terms
Rule 144 regulatory
10b5-1 Sales financial
Restricted Stock Units financial
Exercise of Stock Options financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Which broker is listed for Christine Ring’s proposed NRIX sale?
AI-generated analysis. How Rhea-AI works. Not financial advice.